The invention provides antisense antiviral compounds and methods of their use and production in inhibition of growth of viruses of the Flaviviridae, Picornaviridae, Caliciviridae, Togaviridae, Arteriviridae, Coronaviridae, Astroviridae and Hepeviridae families in the treatment of a viral infection. The antisense antiviral compounds are substantially uncharged morpholino oligonucleotides having a sequence of 12-40 subunits, including at least 12 subunits having a targeting sequence that is complementary to a region associated with stem-loop secondary structure within the 5-terminal end 40 bases of the positive-sense RNA strand of the virus.

Methods of treating a subject suffering from COVID-19 are provided. Aspects of the methods including administering to the subject an effective amount of an inhibitor of CCR5/CCL5 interaction, such as a CCR5 antagonist. Also provided are methods of assessing severity of a disease involving hypercytokinemia, such as COVID-19, by determining the level of CCL5/RANTES in a subject, as well as compositions for use in such methods.

The present invention is directed to a nucleic acid suitable for use in treatment or prophylaxis of an infection with a coronavirus, preferably with a Coronavirus SARS-CoV-2, or a disorder related to such an infection, preferably COVID-19. The present invention is also directed to compositions, polypeptides, and vaccines. The compositions and vaccines preferably comprise at least one of said nucleic acid sequences, preferably nucleic acid sequences in association a lipid nanoparticle (LNP). The invention is also directed to first and second medical uses of the nucleic acid, the composition, the polypeptide, the combination, the vaccine, and the kit, and to methods of treating or preventing a coronavirus infection, preferably a Coronavirus infection.

Disclosed herein are embodiments of a method for collecting, extracting or eluting proteins and antigens from cells infected with coronavirus. The coronavirus may be a porcine coronavirus, such as porcine epidemic diarrhea virus (PEDV) or porcine delta coronavirus (PDCoV). Also disclosed are embodiments of a composition comprising the coronavirus proteins and antigens, and embodiments of a method of using such a composition. Applications for the composition include, but are not limited to, use in the preparation of antibodies against the proteins and antigens, use as reference markers for coronavirus proteins, and/or use in an immunogenic composition, such as in a vaccine composition.

Disclosed herein are glycan-coated RBD immunogens, engineered nanoparticle vaccines comprising glycan-coated RBD immunogens and methods of use thereof for SARS-COV-2 vaccines.

Disclosed herein are embodiments of a method for collecting, extracting or eluting proteins and antigens from cells infected with coronavirus. The coronavirus may be a porcine coronavirus, such as porcine epidemic diarrhea virus (PEDV) or porcine delta coronavirus (PDCoV). Also disclosed are embodiments of a composition comprising the coronavirus proteins and antigens, and embodiments of a method of using such a composition. Applications for the composition include, but are not limited to, use in the preparation of antibodies against the proteins and antigens, use as reference markers for coronavirus proteins, and/or use in an immunogenic composition, such as in a vaccine composition.

The invention relates to a diagnostic kit for multiple detection of 4 viruses of the Family Coronaviridae: HCoV, SARS-CoV, MERS-CoV and the SARS-CoV-2 viral strain that has caused a pandemic of the disease known as COVID-19. The kit uses a One-Step approach with quantitative gene amplification after backward transcription of the viral genome (rRT-PCR). In order to avoid potential false negatives, the invention contains a double control using Porcine Epidemic Diarrhoea Virus (PEDV-CoV) and Ribonuclease P (RNase P-RP).

Disclosed are compositions and methods suitable for treating coronavirus infections. More particularly, disclosed is a proteinaceous agent that prevents or inhibits the replication of a SARS-CoV virus, including a SARS-CoV-2 virus. Also disclosed is the use of these agents and molecules for treating or preventing a coronavirus infection (including a SARS-CoV-2 infection) in a subject.

Highly conserved, short untranslated leader sequences have been identified in MERS-CoV and other human pathogenic Coronaviruses that provide the basis for highly sensitive and accurate assays for these viruses. Use of locked nucleic acids is shown to be useful in amplification reactions for these short sequences. RT-PCR using locked nucleic acids is shown to provide accurate detection of a variety of human pathogen Coronaviruses present at 10 copies per reaction or less.

A new coronavirus is disclosed herein with a tropism that includes humans. Means and methods are provided for diagnosing subjects (previously) infected with the virus. Also provided are among others vaccines, medicaments, nucleic acids and specific binding members.